Sam Brusco, Associate Editor02.17.23
BioSig Technologies announced the US Patent Office has issued a utility patent covering its PURE EP universal notch filtering technology.
Patent No. 11,569,853 was issued on January 31 and is entitled “Universal Notch Filter " and is based on U.S. Application No. 17/591,008 with a priority date of November 8, 2019. The patent describes and claims systems, methods, and computer program product embodiments of the PURE EP System for removing any fixed frequency interfering signal from an input signal without introducing artifacts that are not part of the original signal of interest.
“This latest patent award further demonstrates our commitment to developing technology that protects elaborate cardiac signals and furthers the field of electrophysiology,” Ken Londoner, Chairman, CEO and founder of BioSig told the press. “PURE EP revitalizes the value of the EGM to help EP’s perform insight-based, highly targeted ablation procedures for even the most complex arrhythmias.”
BioSig now has 56 worldwide fundamental granted/allowed, 11 pending U.S. patent applications, and seven European/PCT applications covering its advanced signal processing technology. The company also has 13 pending patent applications in Asia including China, Korea, Japan and, Taiwan.
Patent No. 11,569,853 was issued on January 31 and is entitled “Universal Notch Filter " and is based on U.S. Application No. 17/591,008 with a priority date of November 8, 2019. The patent describes and claims systems, methods, and computer program product embodiments of the PURE EP System for removing any fixed frequency interfering signal from an input signal without introducing artifacts that are not part of the original signal of interest.
“This latest patent award further demonstrates our commitment to developing technology that protects elaborate cardiac signals and furthers the field of electrophysiology,” Ken Londoner, Chairman, CEO and founder of BioSig told the press. “PURE EP revitalizes the value of the EGM to help EP’s perform insight-based, highly targeted ablation procedures for even the most complex arrhythmias.”
BioSig now has 56 worldwide fundamental granted/allowed, 11 pending U.S. patent applications, and seven European/PCT applications covering its advanced signal processing technology. The company also has 13 pending patent applications in Asia including China, Korea, Japan and, Taiwan.